The “2021 China Ophthalmic Market Report” features a new section on corneal diseases and the treatment market, as well as a new regional breakdown of cataract surgeries and patients suffering from glaucoma and dry eye. This report examines the impact of bulk tenders for public hospitals, analyzes the effects of the new Five Year Plan, and lists the leading eye care providers by province. In addition to updated forecasts throughout, the report also features new glaucoma pharmaceutical forecasts by drug class and new forecasts for dry eye by risk group. New ophthalmic product candidates at Chinese pharmaceutical companies also are analyzed.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.